Results 241 to 250 of about 123,607 (301)
Some of the next articles are maybe not open access.
The relationship between lichen planus and metabolic syndrome
Journal of Cosmetic Dermatology, 2020Lichen planus (LP) is an idiopathic, chronic inflammatory disease. Chronic inflammatory diseases can cause metabolic complications. In the literature, data related to the relationship between lichen planus and metabolic syndrome (MS) are limited.
M. Daye, S. Temiz, Begüm Işık
semanticscholar +1 more source
Mast cell expression in oral lichen planus: A systematic review.
Journal of Investigative and Clinical Dentistry, 2019Lichen planus is a common chronic, inflammatory, immune-mediated mucocutaneous disorder affecting the skin and mucosa. The role of mast cells in the genesis of lichen planus has been debated.
J. Vadivel +3 more
semanticscholar +1 more source
Rate of malignant transformation of oral lichen planus: A systematic review.
Oral Diseases, 2018OBJECTIVE The aim of this study was to systematically review the literature to determine: (a) the malignant transformation rate (TR) of oral lichen planus (OLP) and its risk factors; (b) whether or not oral lichenoid lesions (OLL) have a different ...
M. Giuliani +7 more
semanticscholar +1 more source
Clinical and Experimental Dermatology, 1986
Summary The clinical, histological and immunofluorescence findings in a case of lichen ptanus pemphigoides are reported. The pathogenesis and nosological position of the disease is discussed.
C, Oomen, L, Temmerman, A, Kint
openaire +2 more sources
Summary The clinical, histological and immunofluorescence findings in a case of lichen ptanus pemphigoides are reported. The pathogenesis and nosological position of the disease is discussed.
C, Oomen, L, Temmerman, A, Kint
openaire +2 more sources
British Journal of Dermatology, 2019
TCS (topical corticosteroids) are the first‐line drug in the treatment of oral lichen planus (OLP). However, the value of topical calcineurin inhibitors (TCI) including tacrolimus, pimecrolimus and ciclosporin for OLP is still controversial.
S.‐L. Sun +9 more
semanticscholar +1 more source
TCS (topical corticosteroids) are the first‐line drug in the treatment of oral lichen planus (OLP). However, the value of topical calcineurin inhibitors (TCI) including tacrolimus, pimecrolimus and ciclosporin for OLP is still controversial.
S.‐L. Sun +9 more
semanticscholar +1 more source
Lichen planus and lichenoid dermatoses: Clinical overview and molecular basis.
Journal of American Academy of Dermatology, 2018Deriving from the Greek word λειχήν for "tree moss" and the Latin word planus for "planar," lichen planus is a relatively uncommon and heterogeneous cutaneous disorder that typically develops in middle-aged adults. Despite the significant clinical burden
C. Tziotzios +8 more
semanticscholar +1 more source
Australasian Journal of Dermatology, 1998
SUMMARYLichen planus is a relatively common inflammatory dermatosis of unknown origin. The present review summarizes the histological and clinical features of lichen planus and variants, including lichenoid drug reactions, are described. Possible mechanisms of pathogenesis of lichen planus are reviewed. The development of malignancy in association with
openaire +2 more sources
SUMMARYLichen planus is a relatively common inflammatory dermatosis of unknown origin. The present review summarizes the histological and clinical features of lichen planus and variants, including lichenoid drug reactions, are described. Possible mechanisms of pathogenesis of lichen planus are reviewed. The development of malignancy in association with
openaire +2 more sources
Primary Dental Journal, 2016
Lichen planus (LP) is a relatively common autoimmune T-cell-mediated disease of unknown aetiology affecting the mucous membranes, skin and nails. Its prevalence varies between 0.5 and 2.2% of the population in epidemiological studies with a peak incidence in the 30–60 years range and with a female predominance of 2:1.1 Mucosal lichen planus tends to ...
Daniela I, Ion, Jane F, Setterfield
openaire +2 more sources
Lichen planus (LP) is a relatively common autoimmune T-cell-mediated disease of unknown aetiology affecting the mucous membranes, skin and nails. Its prevalence varies between 0.5 and 2.2% of the population in epidemiological studies with a peak incidence in the 30–60 years range and with a female predominance of 2:1.1 Mucosal lichen planus tends to ...
Daniela I, Ion, Jane F, Setterfield
openaire +2 more sources
The Journal of Dermatology, 1992
AbstractWe herein report a case of a rare variety of the acute eruptive form of lichen planus. The patient was a 51‐year‐old male who developed an intensely pruritic eruption on the lower legs which spread rapidly to all four extremities and trunk within a few months. The papulosquamous lesions were more than ten thousand in number.
T, Kanzaki, N, Otake, M, Nagai
openaire +2 more sources
AbstractWe herein report a case of a rare variety of the acute eruptive form of lichen planus. The patient was a 51‐year‐old male who developed an intensely pruritic eruption on the lower legs which spread rapidly to all four extremities and trunk within a few months. The papulosquamous lesions were more than ten thousand in number.
T, Kanzaki, N, Otake, M, Nagai
openaire +2 more sources
SKINmed: Dermatology for the Clinician, 2002
SKINmed: Dermatology for the Clinician spans a readership encompassing nondermatologists and dermatologists. The purpose of this column is twofold: 1) to identify the basic features and typical treatments of commonly encountered skin diseases; and 2) to discuss some of the less commonly used treatments for these diseases.
openaire +2 more sources
SKINmed: Dermatology for the Clinician spans a readership encompassing nondermatologists and dermatologists. The purpose of this column is twofold: 1) to identify the basic features and typical treatments of commonly encountered skin diseases; and 2) to discuss some of the less commonly used treatments for these diseases.
openaire +2 more sources